{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-Induced+Nausea+and+Vomiting+%28CINV%29", "query": { "condition": "Chemotherapy-Induced Nausea and Vomiting (CINV)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-Induced+Nausea+and+Vomiting+%28CINV%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T19:10:47.419Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02116530", "title": "Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)", "type": "DRUG" }, { "name": "Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 401, "start_date": "2014-08-20", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 177, "location_summary": "Anchorage, Alaska • Burbank, California • Dublin, California + 109 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02116530" }, { "nct_id": "NCT06588413", "title": "Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma", "Autologous Stem Cell Transplantation" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2024-09-17", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588413" }, { "nct_id": "NCT06065722", "title": "Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "Akynzeo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Simon Williamson Clinic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-09-09", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "Mount Olive, Alabama", "locations": [ { "city": "Mount Olive", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065722" }, { "nct_id": "NCT00642512", "title": "Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "dronabinol", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "dronabinol/ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solvay Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2003-07", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2008-04-03", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 43, "location_summary": "Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642512" }, { "nct_id": "NCT01500226", "title": "Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Rolapitant", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1369, "start_date": "2012-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-03-02", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500226" }, { "nct_id": "NCT03578081", "title": "Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Palonosetron Hydrochloride", "type": "DRUG" }, { "name": "Ondansetron Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fosaprepitant Dimeglumine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 690, "start_date": "2018-11-20", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 565, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578081" }, { "nct_id": "NCT01499849", "title": "Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Rolapitant", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 532, "start_date": "2012-02", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-05-19", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499849" }, { "nct_id": "NCT03403712", "title": "A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "fosnetupitant/ palonosetron", "type": "DRUG" }, { "name": "netupitant/palonosetron", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 404, "start_date": "2018-03-16", "completion_date": "2018-09-19", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 36, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03403712" }, { "nct_id": "NCT00895245", "title": "Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea and Vomiting", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "fosaprepitant dimeglumine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "palonosetron hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Functional Living Index-Emesis Questionnaire", "type": "OTHER" }, { "name": "Emesis Diary", "type": "BEHAVIORAL" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2009-02", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-05-18", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895245" }, { "nct_id": "NCT00787566", "title": "Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-Induced Nausea and Vomiting" ], "interventions": [ { "name": "Intranasal granisetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shin Nippon Biomedical Laboratories, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-07-12", "last_synced_at": "2026-07-23T19:10:47.419Z", "location_count": 1, "location_summary": "The Study Is Managed by Kendle International, in Wilmington, North Carolina", "locations": [ { "city": "The Study Is Managed by Kendle International, in Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787566" } ] }